SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

Leading on Studying Short DAPT

Boston Scientific is committed to clinical science that meets what physicians encounter in their everyday practice, including the need for shortened DAPT. We are studying shortened DAPT with the SYNERGY Bioabsorbable Polymer (BP) Stent in various patient populations.

Indications, Safety, and Warnings

Request a Sales Rep

SENIOR*

1-month DAPT in stable elderly patients
6-month DAPT in ACS elderly patients

View the SENIOR Trial data

1,200 Patients
SYNERGY BP-DES vs REBEL™ BMS

2-Year Data Now Available

EVOLVE Short DAPT

3-month DAPT in HBR patients

View the EVOLVE Short DAPT
Trial data >

2,009 Patients
IDE Trial | SYNERGY BP-DES

0-3 Months Baseline Data Now Available

IDEAL Left Main*^†

4-month DAPT in Left Main with SYNERGY BP-DES
12-month DAPT in Left Main with Xience™ PP-DES

818 Patients
Left Main PCI

Completed Enrollment

ASET*

0-month DAPT in patients with chronic stable angina

200 Patients
SYNERGY BP-DES

Completed Enrollment

POEM*

1-month DAPT in HBR patients

443 Patients
SYNERGY BP-DES

Completed Enrollment

SYNIVUS-DAPT*

1-month DAPT in HBR patients

100 Patients
SYNERGY BP-DES
IVUS

Ongoing Enrollment

Early Healing

Early Healing

Advanced design for optimal healing

Clinical Outcomes

Clinical Outcomes

Outstanding evidence across trials

Efficiency

Efficiency

How design impacts economic value

Top